KPV + GHK-Cu

What is the KPV + GHK-Cu blend?

KPV is lysine–proline–valine, the C-terminal residues 11–13 of alpha-melanocyte-stimulating hormone. Preclinical research focuses on inflammatory signaling, PepT1-mediated transport, epithelial biology, and intestinal inflammation models.

GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine. Cell, animal, and limited human topical research focuses on copper transport, extracellular-matrix remodeling, collagen, fibroblasts, inflammatory signaling, and wound biology.

The combination places a copper-associated matrix-signaling peptide and an alpha-MSH-derived inflammatory-signaling peptide into the same fixed exposure. That is a research hypothesis — not evidence of synergy.

Common 60 mg composition

This 50/10 mg configuration is commercially documented, but it is not a pharmacologically standardized ratio. Some sellers offer different strengths. A label that says only “KPV/GHK-Cu 60 mg” is incomplete unless it states the amount of each component.

A 5:1 mass ratio is not necessarily a 5:1 molar ratio. Using approximate molecular masses, the GHK-Cu:KPV molar ratio is approximately 4.26:1 if KPV is free-base mass, or 5.01:1 if KPV is total 1:1 acetate-salt mass.

Identity and label checks

KPV free base versus KPV acetate are distinct materials. FDA's 2026 chemistry review reported ~0.7 mg/mL water solubility for free base and ~5 mg/mL for acetate. Labels must clarify whether milligrams mean active peptide, salt, or total solids.

GHK versus GHK-Cu: GHK is the copper-free ligand; GHK-Cu is the copper complex. For a representative 401.9 g/mol one-copper complex, copper contributes approximately 15.81% of complex mass (~158 mcg Cu per 1 mg GHK-Cu).

Current research and compounding status

There is no prescribing information or standardized drug dosage for the KPV + GHK-Cu blend. In July 2026, an FDA advisory committee recommended KPV free base and KPV acetate for the section 503A bulks list — advisory only, and not an evaluation of this combination. Non-injectable GHK-Cu remains separately under evaluation.

Available 60 mg schedules are community conventions — not approved prescribing protocols.

Has the exact KPV + GHK-Cu blend been studied?

No controlled human or animal study of the exact 50 mg GHK-Cu + 10 mg KPV blend was identified through August 2026. A 2025 tripeptide review discusses KPV and GHK-Cu within wound and skin research, but reviews separate molecule-specific evidence rather than testing this premixed product.

Dosage used in human clinical research

Exact combination: No human dose has been studied for the KPV + GHK-Cu combination.

KPV: FDA's 2026 review did not identify a study in which isolated KPV was administered to people by any route.

GHK-Cu: Human research is concentrated in topical formulations — diabetic neuropathic-ulcer trial, facial/eye-area studies, and CO₂-laser resurfacing (mixed results). No controlled human study of subcutaneous GHK-Cu dosing was identified.

KPV + GHK-Cu research dosage

The most specific traceable range is 1.5–2.5 mg GHK-Cu + 300–500 mcg KPV per administration (= 1.8–3 mg total), once daily, five days weekly, for 8–12 weeks. The detailed escalation can be traced to one contemporary 60 mg product guide — treat as one documented convention, not consensus.

Complete reported 12-week KPV + GHK-Cu research protocol

The following schedule reproduces the most specific traceable 60 mg protocol. It assumes a 50/10 mg vial prepared to 3 mL (20 mg/mL total). One U-100 unit = 0.01 mL = 200 mcg total blend (≈166.7 mcg GHK-Cu + 33.3 mcg KPV).

This is an anecdotally reported research escalation, not a human clinical protocol. Escalation should occur only if predefined tolerability criteria are met. Because the vial is fixed at 5:1, reducing the draw lowers both components simultaneously.

Hold/stop examples: persistent injection-site reaction; allergic symptoms; abnormal copper, liver, or kidney findings; product instability (cloudiness, particulates); worsening target condition. Urgent symptoms require medical evaluation — not dose adjustment.

Vial inventory: 150 mg nominal cycle = 2.5 reference vials → three 60 mg vials before handling loss. At 3 mg five times weekly, one vial provides ~20 administrations (~4 weeks).

Fixed-dose research variations

Fixed exposures are easier to interpret than changing doses. The following are mathematical simplifications of the documented 1.8–3 mg range — not independently validated protocols.

Reconstitution and concentration math

These tables are calculation references, not validated formulation recipes. For the 50/10 mg reference vial: Units for total amount D = 100 × V × D ÷ (G + K) where G = GHK-Cu mg, K = KPV mg, V = diluent mL.

Solubility can invalidate correct arithmetic. KPV concentration in a 50/10 mg blend: 5 mg/mL at 2 mL, 3.33 mg/mL at 3 mL, 2.5 mg/mL at 4 mL — compare against FDA-reported free-base (~0.7 mg/mL) and acetate (~5 mg/mL) solubility.

Reported KPV + GHK-Cu dosage range

Anecdotal versus clinically studied dosing

Preclinical research dosage

Animal and laboratory research only. No exact-combination animal dose was identified. Component-specific exposures should not be converted into a human blend dose.

Models differ in species, disease, route, timing, and endpoint. Body-surface-area conversion cannot transform them into an evidence-based 5:1 subcutaneous human protocol.

Why these reported doses are used

1. 5:1 ratio alignment — The 50/10 mg vial pairs every 1 mg GHK-Cu with 200 mcg KPV. GHK-Cu community injection pages often report 1–2 mg; KPV pages report 200–500 mcg. This arithmetic alignment likely explains the ratio better than receptor biology.
2. Five-days-on/two-days-off — Often described as a tolerability feature. No human study showed this pattern prevents desensitization or changes copper handling.
3. Eight-to-twelve-week duration — Topical GHK-Cu studies often ran 8–12 weeks; community injection schedules appear to borrow that window. KPV has no human duration study.
4. Gradual escalation — Creates distinct observation phases but cannot identify component-specific dose-response because both peptides increase together.

How the blend may work

KPV reduced NF-kappa-B and MAP-kinase signaling in selected intestinal epithelial systems. PepT1 can transport the tripeptide in intestinal models. Human subcutaneous PK remains unknown.

GHK-Cu is studied as a copper carrier and signaling complex affecting collagen, elastin, metalloproteinases, fibroblast activity, antioxidant pathways, and repair-cell recruitment.

The blend is commonly framed as pairing inflammatory control with matrix remodeling — a mechanistic hypothesis assembled from separate literatures. It does not show the two molecules reach the same tissue, remain intact for the same duration, or outperform either alone.

Route variations

Common claims vs evidence

Dosage evidence ladder

KPV + GHK-Cu dosing is poorly established. The 50/10 mg vial and 1.8–3 mg schedule are precise community conventions, but no controlled study establishes their safety, efficacy, PK, ratio, frequency, or duration.

Safety and adverse effects

No controlled dataset can provide incidence, severity, or dose relationship of adverse effects from KPV + GHK-Cu. A fixed-ratio vial creates an attribution problem: changing the draw changes both peptides and copper exposure at once.

Particular caution is warranted with copper-metabolism disorders, significant liver disease, active infection, autoimmune disease, or concurrent immunosuppressive therapy. Do not substitute peptide use for standard medical evaluation of wounds, infections, or inflammatory conditions.

Storage and stability

No published stability study establishes a universal storage period for a 50/10 mg KPV + GHK-Cu solution. Community protocols commonly refrigerate reconstituted solutions at 2–8°C and cite 28 days — a handling convention, not stability-indicating data for every blend.

A blue solution is consistent with coordinated copper, but color does not prove correct potency, ratio, sterility, or KPV dissolution. Unexpected cloudiness, precipitation, or particulates should invalidate controlled exposure until investigated.

Anti-doping considerations

The 2026 WADA list applies S0 Non-Approved Substances to pharmacological substances without current governmental health-authority approval for human therapeutic use. KPV and GHK-Cu do not need to be individually named for S0 to be relevant. Tested athletes should obtain sport-specific guidance.

Bottom line

KPV + GHK-Cu is a biologically plausible but clinically untested two-tripeptide blend. The most clearly documented vial contains 50 mg GHK-Cu + 10 mg KPV at a fixed 5:1 mass ratio. The most specific reported protocol gradually increases from 1.5 mg GHK-Cu + 300 mcg KPV to 2.5 mg + 500 mcg, five days weekly for up to 12 weeks.

That full schedule uses 125 mg GHK-Cu and 25 mg KPV (150 mg total blend; three vials before loss). With 3 mL per 60 mg vial, draws progress from 9 to 15 U-100 units. These calculations are internally consistent, but the schedule remains a community/vendor convention without exact-combination human PK, efficacy, or long-term safety evidence.

Confirm vial ratio, KPV form (free base vs acetate), GHK-Cu copper occupancy, theoretical copper exposure, KPV solubility at chosen concentration, and mixed-vial stability — before trusting any unit chart.

Frequently asked questions

References

• FDA

  KPV-related bulk drug substances: 2026 PCAC briefing document

  Chemistry, solubility, and no human KPV exposure study.

• FDA

  July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting

  Advisory votes — not blend evaluation.

• Dalmasso G et al.

  PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

  2008.

• Pickart L, Margolina A.

  Regenerative and protective actions of GHK-Cu

  2018 review — topical/lab context.

• Mulder GD et al.

  Topical GHK-Cu in diabetic neuropathic ulcers

  1994 — not injectable blend dosing.

• Adnan SB et al.

  Tripeptides in wound healing and skin regeneration: comprehensive review

  2025 — separate molecule evidence, not exact blend.

• Pure Performance Labs

  KPV + GHK-Cu 60 mg reference protocol

  Community protocol source — documents reported practice.

• WADA

  2026 Prohibited List

  S0 non-approved substances category.